[144] Kiniksa Pharmaceuticals International, plc SEC Filing

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) has filed a Form 144 to notify the SEC of an intended insider sale.

• Shares to be sold: 64,508 common shares
• Aggregate market value: $1,928,595.68
• Approximate sale date: 07/30/2025
• Broker: Morgan Stanley Smith Barney LLC, New York
• Shares outstanding: 74,107,668

The shares were acquired the same day (07/30/2025) through the exercise of employee stock options under a registered plan and will be sold for cash. No other sales by this insider were reported in the past three months.

The proposed disposition equals roughly 0.09% of total shares outstanding, indicating a modest, routine-sized transaction rather than a large liquidation. The filer attests to having no undisclosed material adverse information and confirms compliance with Rule 10b5-1.

Positive

• None.

Negative

• Insider plans to sell 64,508 shares (~0.09% of 74.1 M outstanding) valued at $1.93 M

Insights

Securities Analyst

TL;DR: Small insider sale (0.09% OS) worth $1.9 M; signals routine diversification, limited fundamental impact.

The Form 144 shows an insider intends to sell 64,508 newly-exercised option shares, worth about $1.93 million, through Morgan Stanley on 07/30/2025. Given 74.1 million shares outstanding, the sale is immaterial to float and does not suggest broad insider pessimism. Lack of prior 3-month sales and same-day option exercise point to liquidity/tax planning rather than a directional bet. Investors typically view such filings as neutral unless accompanied by larger cluster selling. I rate the filing neutral for valuation and trading outlook.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	64508	1928595.68	74107668	07/30/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/30/2025	Exercise of options under a registered plan	Issuer			18760	07/30/2025	Cash
Common	07/30/2025	Exercise of options under a registered plan	Issuer			45748	07/30/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many KNSA shares are being sold under this Form 144?

64,508 common shares are slated for sale.

What is the aggregate market value of the planned Kiniksa insider sale?

The filing lists an aggregate value of $1,928,595.68.

When is the approximate sale date for the KNSA shares?

The filer indicates an approximate sale date of 07/30/2025.

What percentage of KNSA's outstanding shares does this sale represent?

The 64,508 shares equal roughly 0.09% of the 74,107,668 shares outstanding.

Were there any other insider sales reported in the past three months?

No. The Form 144 states "Nothing to Report" for the prior three-month period.

How were the shares acquired prior to the sale?

They were obtained via option exercises under a registered plan on 07/30/2025 for cash.